Mi az ára Coeptis Therapeutics Holdings, Inc. (COEP)

Coeptis Therapeutics Holdings, Inc. (COEP) ára $4.81

Mi a Coeptis Therapeutics Holdings, Inc. (COEP piaci tőkésítése)

Coeptis Therapeutics Holdings, Inc. piaci tőkésítése (COEP) $29.01M

Coeptis Therapeutics Holdings, Inc. (COEP) Bevétel

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Év	Bevétel	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Bevétel

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Bevétel	Bevételkülönbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Moderna, Inc. MRNA.US	$2.23B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

Bevétel

Bevételkülönbség

Ország